Commercially available ocular drug delivery systems are effective but less efficacious to manage diseases/disorders of the anterior segment of the eye. Recent advances in nanotechnology and molecular biology offer a great opportunity for efficacious ocular drug delivery for the treatments of anterior segment diseases/disorders. Nanoparticles have been designed for preparing eye drops or injectable solutions to surmount ocular obstacles faced after administration. Better drug pharmacokinetics, pharmacodynamics, non-specific toxicity, immunogenicity, and biorecognition can be achieved to improve drug efficacy when drugs are loaded in the nanoparticles. Despite the fact that a number of review articles have been published at various points in the past regarding nanoparticles for drug delivery, there is not a review yet focusing on the development of nanoparticles for ocular drug delivery to the anterior segment of the eye. This review fills in the gap and summarizes the development of nanoparticles as drug carriers for improving the penetration and bioavailability of drugs to the anterior segment of the eye.

市售的眼用药物递送系统对于治疗眼前节的疾病/病症是有效的，但效果较差。纳米技术和分子生物学的最新进展为有效治疗眼前段疾病/疾病的眼部药物输送提供了巨大的机会。纳米颗粒已被设计用于制备滴眼剂或注射液，以克服给药后面临的眼部障碍。当将药物装载在纳米颗粒中时，可以实现更好的药物药代动力学，药效学，非特异性毒性，免疫原性和生物识别性，从而提高药物功效。尽管过去在不同地方发表了许多有关用于药物递送的纳米颗粒的评论文章，尚无关于将纳米药物用于眼部药物递送至眼前段的纳米颗粒的开发的评论。这篇综述填补了空白，并总结了纳米颗粒作为药物载体的发展，以改善药物对眼前段的渗透性和生物利用度。